Microbix Advances Kinlytic Urokinase Production with New CDMO Agreement

Microbix Biosystms ( (TSE:MBX) ) has shared an update.

Microbix Biosystems Inc. announced that its partner, Sequel Pharma, has signed an agreement with a contract development and manufacturing organization (CDMO) to produce Kinlytic® urokinase, a drug for dissolving blood clots. This agreement aims to resume production for the U.S. market, initially targeting the catheter clearance segment valued at $400 million. The collaboration is expected to enhance Microbix’s market presence and operational capabilities, with future updates anticipated as the project progresses.

Spark’s Take on TSE:MBX Stock

According to Spark, TipRanks’ AI Analyst, TSE:MBX is a Neutral.

Microbix Biosystems scores a 68, reflecting strong financial performance and positive earnings call insights. Technical analysis offers mixed signals, and valuation concerns persist with a high P/E ratio. The company’s strategic growth and stable financial position are key strengths, though the competitive and capital-intensive nature of the biotechnology sector presents ongoing challenges.

To see Spark’s full report on TSE:MBX stock, click here.

More about Microbix Biosystms

Microbix Biosystems Inc. is a life sciences company that creates proprietary biological products for human health. It focuses on manufacturing critical ingredients and devices for the global diagnostics industry, including antigens for immunoassays and laboratory quality assessment products (QAPs). These products support clinical lab proficiency testing and ensure the quality of clinical diagnostic workflows. Microbix operates internationally, with products available in over 30 countries, and is accredited by various health authorities.

YTD Price Performance: -3.70%

Average Trading Volume: 123,170

Technical Sentiment Signal: Sell

Current Market Cap: C$55M

Find detailed analytics on MBX stock on TipRanks’ Stock Analysis page.